OmniAb, Inc. (OABI) earnings date
Mar 17, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 37 days, typically, give or take 16 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Fri, Oct 30, 2026 | before open | 30 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Wed, Mar 4, 2026 | after close | 63 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | after close | 35 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | after close | 37 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | after close | 38 | 8-K |
| Q4 FY2024 | Tue, Mar 18, 2025 | after close | 77 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights Raises Full Year 2026 Revenue and Cash Outlook on Continued Business Momentum Conference Call to Begin Today at 8:00 a.m. ET EMERYVILLE, Calif." exhibit |
| Q3 FY2026 | "(October 30, 2026) – OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and nine months ended September 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance." exhibit |
| Q3 FY2026 | "Research and development expense was $9.6 million for the third quarter of 2026, compared with $10.4 million for the same period in 2025, with the decrease due to lower personnel expense related to share-based compensation and salary expense and lower facility-related costs." exhibit |
| Q3 FY2026 | "General and administrative expense was $7.2 million for the third quarter of 2026, compared with $6.8 million for the same period in 2025, with the increase primarily due to higher external expenses, including legal and other public company expenses and was partially offset by lower personnel expense related to share-based compensation." exhibit |
| Q3 FY2026 | "Research and development expense was $28.8 million for the nine months ended September 30, 2026, compared with $33.8 million for the same period in 2025, with the decrease due to lower personnel expense related to share-based compensation and salary expense, lower external expenses primarily from certain antibody programs, and lower facility-related costs." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights Raises Full Year 2026 Revenue and Cash Outlook Driven by Continued Business Momentum Conference Call to Begin Today at 4:30 p.m. ET EMERYVILLE, Calif." exhibit |
| Q2 FY2026 | "(August 6, 2026) – OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and six months ended June 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance." exhibit |
| Q2 FY2026 | "“We are pleased to report a strong quarter and to increase our revenue and cash outlook for 2026 based on continued momentum in our business." exhibit |
| Q2 FY2026 | "Research and development expense was $9.6 million for the second quarter of 2026, compared with $10.9 million for the same period in 2025, with the decrease due to lower personnel expense related to share-based compensation and salary expense and lower facility-related costs." exhibit |
| Q2 FY2026 | "General and administrative expense was $6.7 million for the second quarter of 2026, compared with $7.7 million for the same period in 2025, with the decrease primarily due to lower personnel expense related to share-based compensation and salary expense and lower professional fees." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/OABI
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/OABI
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/OABI/"><img src="https://veritasdata.dev/embed/OABI.svg" alt="OABI earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/OABI/)
Script
<script async src="https://veritasdata.dev/embed/OABI.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/OABI"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.